Actionable genomic landscape remains stable across serial circulating tumor DNA analyses in advanced breast cancer
In advanced breast cancer, repeat comprehensive ctDNA profiling is highly valuable for initially non-contributive samples but yields limited new actionable targets after a successful first assay, suggesting that targeted ESR1 monitoring is a more efficient strategy for patients with prior contributive results.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the fight against advanced breast cancer, doctors have increasingly turned to a tool called liquid biopsy. Instead of cutting into the body to remove a piece of a tumor, they draw a small vial of blood. Inside that blood float tiny fragments of DNA shed by the cancer cells, acting like a molecular signature of the disease. By reading this genetic code, physicians can identify specific weaknesses in the tumor that might be targeted by new drugs. This approach has become a standard way to guide treatment, especially for patients whose cancer has spread. However, as the disease evolves and patients move through different lines of therapy, a practical question has emerged: if a doctor has already read the cancer's genetic code once, is it necessary to read it again and again? Does the tumor change its genetic makeup so quickly that a fresh test reveals entirely new targets, or does the initial reading remain reliable over time?
Researchers at the Gustave Roussy cancer center in France set out to answer this question by looking at the records of 152 patients with advanced breast cancer. These patients had undergone at least two comprehensive genetic tests on their blood samples over the course of their treatment. The team wanted to know if repeating these broad tests, which scan hundreds of genes at once, would uncover new, actionable targets that were missed the first time, or if the genetic landscape of the cancer remained largely the same. They also wanted to understand what happens when the first test fails to find any cancer DNA, and whether a second attempt is worth the effort.
The study began by sorting the patients based on the results of their first blood test. In 87 of the 152 patients, the first test was successful, meaning it detected enough tumor DNA to provide a clear genetic profile. In the remaining 65 patients, the first test came back empty, finding no detectable tumor DNA. For those 65 patients, the researchers watched what happened when they tested again later. The results were encouraging: nearly 71 percent of these patients, or 46 out of 65, eventually tested positive on a subsequent blood draw. This suggests that a negative first result does not mean the cancer lacks genetic targets; it often just means the tumor was not shedding enough DNA into the blood at that specific moment. The researchers noted that patients with cancer that had spread only to the bones were more likely to have these persistent negative results, likely because bone tumors are less likely to release DNA into the bloodstream compared to tumors in organs like the liver.
For the patients who had successful tests, the researchers compared the genetic profiles from their first successful blood draw with their next successful one. They found that the genetic picture of the cancer was remarkably stable. The specific genes driving the cancer did not change significantly between tests. When they looked at the genes that could be targeted by drugs, the results from the first test matched the results from the second test with a very high degree of agreement. New genetic changes that appeared in the second test were rare. In fact, among the patients who had two successful tests, only a small fraction developed a new, targetable genetic change that was not present in the first test. Most of the new changes that did appear were either very minor, existing in only a tiny fraction of the cancer cells, or were unrelated to the tumor itself, arising instead from normal changes in the blood cells.
One notable exception to this stability was a specific gene called ESR1. In a small group of patients, a mutation in this gene appeared later in the disease course. This mutation is known to help cancer resist certain hormonal treatments, and its emergence is a well-known reason to switch therapies. However, aside from this specific case, the broad search for new targets in a second comprehensive test rarely yielded new information. The researchers calculated that when patients were matched to clinical trials or new treatments based on their genetic profiles, fewer than one in five of those matches came from a re-test. The vast majority of treatment opportunities were identified in the very first successful test.
These findings suggest a clear path forward for how doctors should use liquid biopsies. If the first test fails to find cancer DNA, repeating the test later is highly valuable, as it often succeeds where the first one failed. However, if the first test is successful and provides a full genetic profile, running the same broad, expensive test again is unlikely to change the treatment plan. Instead of repeating the full scan, the researchers propose that doctors should focus on targeted monitoring for specific changes, such as the ESR1 mutation, when patients are on hormonal therapy. This approach would allow doctors to catch the few changes that matter without subjecting patients to unnecessary testing. The study concludes that the initial genetic reading of a tumor is a durable map, and while the terrain may shift slightly at the edges, the main landmarks remain in place, guiding treatment decisions effectively for a long time.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.